• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc.

    7/12/24 6:17:25 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYCN alert in real time by email
    SC 13G/A 1 d817118dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 4)

     

     

    Cyclerion Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, no par value

    (Title of Class of Securities)

    23255M105

    (CUSIP Number)

    July 12, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Bermuda

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     115,603

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     115,603

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     115,603

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.3%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    2


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities Advisors, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     115,603

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     115,603

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     115,603

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.3%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    3


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Bermuda

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     552

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     552

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     552

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     Less than 0.1%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    4


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Advisors, L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     552

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     552

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     552

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     Less than 0.1%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    5


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International S.C.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     116,155

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     116,155

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     116,155

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.3%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    6


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International Management S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     116,155

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     116,155

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     116,155

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.3%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    7


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal Group S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     116,155

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     116,155

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     116,155

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.3%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    8


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Westend S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     116,155

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     116,155

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     116,155

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.3%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    9


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Stichting Administratiekantoor Westend

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     116,155

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     116,155

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     116,155

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.3%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    10


    CUSIP No. 23255M105

       13G   

     

     1   

     NAMES OF REPORTING PERSONS

     

     Mr. Amaury Wittouck

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Belgium

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     116,155

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     116,155

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     116,155

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.3%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    11


    Item 1(a).    Name of Issuer:
       Cyclerion Therapeutics, Inc. (the “Issuer”)
    Item 1(b).    Address of Issuer’s Principal Executive Offices:
       245 First Street, 18th Floor, Cambridge, Massachusetts 02142
    Item 2(a).    Name of Person Filing:
    Item 2(b).    Address of Principal Business Office or, if none, Residence:
    Item 2(c).    Citizenship:
      

    (i) Invus Public Equities, L.P. (“Invus Public Equities”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

       Citizenship: Bermuda limited partnership
      

    (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

       Citizenship: Delaware limited liability company
      

    (iii) Invus, L.P.

    750 Lexington Avenue, 30th Floor, New York, NY 10022

       Citizenship: Bermuda limited partnership
      

    (iv) Invus Advisors, L.L.C. (“Invus Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

       Citizenship: Delaware limited liability company
       (v) Artal International S.C.A. (“Artal International”)
       Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg
       Citizenship: Luxembourg limited partnership
       (vi) Artal International Management S.A. (“Artal International Management”)
       Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg
       Citizenship: Luxembourg société anonyme
       (vii) Artal Group S.A. (“Artal Group”)
       Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg
       Citizenship: Luxembourg société anonyme
       (viii) Westend S.A. (“Westend”)
       Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg
       Citizenship: Luxembourg société anonyme
       (ix) Stichting Administratiekantoor Westend (the “Stichting”)
       Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands
       Citizenship: Netherlands foundation
       (x) Mr. Amaury Wittouck
       Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg
       Citizenship: Belgium
    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
    Item 2(d).    Title of Class of Securities:
       Common Stock, no par value (the “Shares”)
    Item 2(e).    CUSIP Number:
       23255M105

     

    12


    Item 3.

    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    This Item 3 is not applicable.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    Invus Public Equities directly holds 115,603 Shares and Invus, L.P. directly holds 552 Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Invus Advisors as the general partner of Invus, L.P. controls Invus, L.P. and, accordingly, may be deemed to beneficially own the Shares directly held by Invus, L.P. The Geneva branch of Artal International, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Artal International, as the managing member of Invus Advisors, controls Invus Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus Advisors may be deemed to beneficially own. Artal International Management, as the managing partner of Artal International, controls Artal International and, accordingly, may be deemed to beneficially own the Shares that Artal International may be deemed to beneficially own. Artal Group, as the sole stockholder of Artal International Management, controls Artal International Management and, accordingly, may be deemed to beneficially own the Shares that Artal International Management may be deemed to beneficially own. Westend, as the parent company of Artal Group, controls Artal Group and, accordingly, may be deemed to beneficially own the Shares that Artal Group may be deemed to beneficially own. The Stichting, as the majority stockholder of Westend, controls Westend and, accordingly, may be deemed to beneficially own the Shares that Westend may be deemed to beneficially own. Mr. Wittouck, as the sole member of the board of the Stichting, controls the Stichting and, accordingly, may be deemed to beneficially own the Shares that the Stichting may be deemed to beneficially own.

    (b) Percent of class:

    As of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person’s cover page. Calculations of the percentage of Shares beneficially owned are based on 2,710,096 Shares outstanding as of May 3, 2024 based on information set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2024.

    (c) As of the date hereof, each of Invus Public Equities and Invus PE Advisors has the sole power to vote or direct the vote and the sole power to dispose or direct the disposition of the 115,603 Shares directly held by Invus Public Equities. As of the date hereof, each of Invus, L.P. and Invus Advisors has the sole power to vote or direct the vote and the sole power to dispose or direct the disposition of the 552 Shares directly held by Invus, L.P.

    As of the date hereof, each of Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck has the sole power to vote or direct the vote and the sole power to dispose or direct the disposition of the 115,603 Shares directly held by Invus Public Equities and the 552 Shares directly held by Invus, L.P.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

     

    13


    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    This Item 9 is not applicable.

     

    Item 10.

    Certification.

    Each of the Reporting Persons hereby makes the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    14


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: July 12, 2024

     

    INVUS PUBLIC EQUITIES, L.P.
    By:   INVUS PUBLIC EQUITIES ADVISORS, LLC, its general partner
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    INVUS PUBLIC EQUITIES ADVISORS, LLC
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    INVUS, L.P.
    By:   INVUS ADVISORS, L.L.C., its general partner
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    INVUS ADVISORS, L.L.C.
    By:   /s/ Raymond Debbane
    Name:   Raymond Debbane
    Title:   President
    ARTAL INTERNATIONAL S.C.A.
    By:   ARTAL INTERNATIONAL MANAGEMENT S.A., its managing partner
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director


    ARTAL INTERNATIONAL MANAGEMENT S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director
    ARTAL GROUP S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Authorized Person
    WESTEND S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director
    STICHTING ADMINISTRATIEKANTOOR WESTEND
    By:   /s/ Amaury Wittouck
    Name:   Amaury Wittouck
    Title:   Sole Member of the Board
    MR. AMAURY WITTOUCK
    By:   /s/ Amaury Wittouck
    Get the next $CYCN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYCN

    DatePrice TargetRatingAnalyst
    10/20/2021$14.00Buy
    Truist Securities
    9/24/2021$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYCN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cyclerion Therapeutics Inc.

    SCHEDULE 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)

    8/14/25 4:05:22 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cyclerion Therapeutics Inc.

    10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)

    8/5/25 4:30:55 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Cyclerion Therapeutics Inc.

    8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)

    6/18/25 4:41:21 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Chicko Rhonda M.

    4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)

    8/11/25 4:05:06 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hecht Peter M was granted 181,818 shares, increasing direct ownership by 48% to 559,203 units (SEC Form 4)

    4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)

    3/27/25 8:38:03 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Higgins Michael J was granted 9,090 shares, increasing direct ownership by 42% to 30,740 units (SEC Form 4)

    4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)

    3/27/25 4:20:44 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist Securities initiated coverage on Cyclerion Therapeutics with a new price target

    Truist Securities initiated coverage of Cyclerion Therapeutics with a rating of Buy and set a new price target of $14.00

    10/20/21 7:03:08 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Cyclerion Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Cyclerion Therapeutics with a rating of Overweight and set a new price target of $7.00

    9/24/21 7:19:43 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

    CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution. "These agreements demonstrate Cyclerion's progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets," said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. "These newly finalized agreements, combined with our significant redu

    12/17/24 8:08:11 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regina Graul, Ph.D., Promoted to Chief Executive Officer

    CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December 2023, she has strengthened all aspects of the company. She has been working closely with the Board of Directors to prioritize building shareholder value by reducing Cyclerion's operating costs while leading a world-class search and evaluation team, currently triaging multiple business development prospects for which Cyclerion believes it is well suited. "From the day Regina arrived at Cyclerio

    8/7/24 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclerion Appoints Regina Graul, Ph.D., as President

    – Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work close

    12/4/23 8:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    Leadership Updates

    Live Leadership Updates

    View All

    Cyclerion Appoints Regina Graul, Ph.D., as President

    – Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work close

    12/4/23 8:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

    Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS) Study in Alzheimer's Disease with vascular pathology (ADv) enrollment ongoing Appointed Steven E. Hyman, M.D. to its Board of Directors CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022 financial results and a business update. "The data generated from our recent

    8/9/22 4:00:00 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

    CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25. Dr. Hyman will work with Cyclerion leadership to help shape the future of its research and clinical development strategy while expanding external collaborations with scientific leaders and industry partners. "We are delighted to welcome Dr. Steve Hyman to Cyclerion. Steve is a world-renowned leader in neuroscience with deep expertise leading large-scale, collaborative research program

    7/26/22 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc.

    SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)

    7/12/24 6:17:25 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc. (Amendment)

    SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)

    2/14/24 4:05:40 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc. (Amendment)

    SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)

    2/9/24 5:06:49 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care